# A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma

> **NCT07651618** · PHASE2 · NOT_YET_RECRUITING · sponsor: **East Metropolitan Health Service, Australia** · enrollment: 10 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)
- Melanoma Metastatic

## Interventions

- **BIOLOGICAL:** Tumour Infiltrating Lymphocytes Adoptive Cell Therapy
- **DRUG:** Cyclophosphamide + Fludarabine Lymphodepletive Conditioning
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT07651618
- **Lead sponsor:** East Metropolitan Health Service, Australia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-07
- **Final completion:** 2032-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07651618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07651618, "A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07651618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*